このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

BoMI for Muscle Control

2020年11月17日 更新者:Ferdinando Mussa-Ivaldi、Shirley Ryan AbilityLab

Body-Machine Interface for Recovering Muscle Control

People with spinal cord injury (SCI), stroke and other neurodegenerative disorders can follow two pathways for regaining independence and quality of life. One is through clinical interventions, including therapeutic exercises. The other is provided by assistive technologies, such as wheelchairs or robotic systems. In this study, we combine these two paths within a single framework by developing a new generation of body-machine interfaces (BoMI) supporting both assistive and rehabilitative goals. In particular, we focus on the recovery of muscle control by including a combination of motion and muscle activity signals in the operation of the BoMI.

調査の概要

詳細な説明

When suffering from conditions affecting the central nervous system, such as spinal cord injury (SCI), stroke or neurodegenerative disorders, two pathways are available for regaining independence and quality of life. One way is through clinical interventions, including therapeutic exercises, often in combination with pharmacological agents. The other is provided by assistive technologies, such as wheelchairs or robotic systems. These two approaches have conflicting characteristics. While rehabilitation exercises challenge patients to use the most affected parts of their musculoskeletal apparatus, assistive technologies are typically designed to bypass the disability. This has led to divergent research domains. In both fields there are three major gaps that we plan to address in the investigator's research:

  1. High cost of technology and the limited amount of available hospital-based rehabilitation;
  2. Lack of adaptability of currently available assistive technologies, such as head switches and sip-and puff devices, that require users to overcome a hard learning barrier;
  3. Inadequate criteria for assessment of effectiveness of therapy, with common techniques still relying on subjective approaches that are inadequate considering the current state of biomedical science and technology.

We will address all of these issues by developing a new generation of body-machine interfaces (BoMI) supporting both assistive and rehabilitative goals. BMIs will translate movement signals and muscle activities of the user into control signals for assistive devices and computer systems. State-of-the-art systems for surface electromyography (EMG) and movement recording (IMU) will be integrated through machine learning techniques to facilitate sensorimotor learning while providing the means to promote or reduce the use of targeted muscles. New comprehensive assessment techniques will be developed by integrating standard measure of function - as the manual muscle test - with EMG analysis and non-invasive magnetic brain stimulation (TMS) (Magstim 200 Bistim, Whitland, UK). The development will be organized in three specific aims.

AIM 1: To develop a BMI integrating muscle activities and motion signals for operating external devices and performing rehabilitation exercises. EMG signals derived from multiple muscles in the upper body (e.g. deltoid, pectoralis, trapezius, triceps, etc.) will be integrated with motion signals to generate control signals for external devices (e.g. the coordinates of a cursor on a computer monitor or the speed and direction commands to a powered wheelchair). Both linear (PCA) and nonlinear maps (auto encoder networks) will be explored, although current preliminary evidence suggests that non-linear auto encoders (AE) are likely to better facilitate user learning1.

AIM 2: To enable targeting and modulating recruitment of specific muscles and muscle synergies during the practice of games and functional tasks. To enhance or reduce the role of a muscle or synergy, the output of the BoMI will be modulated in proportion to the deviation of the measured muscle activity from the desired level. The effectiveness of the approach will be tested at different times following training, both by tracking of motions and EMG activities during the performance of selected activities of daily living (ADL) and trough the assessment of muscle responses evoked by non-invasive brain stimulation.

AIM 3: To promote the adoption of the BoMI by facilitating access to its functions by patients and therapists and by performing an observational study on uptake in the DayRehabTM environment. The Shirley Ryan Ability Lab has established a unique environment in which spinal cord injured and stroke outpatients engage in daily rehabilitation exercises in close physical proximity with researchers. We will seize this opportunity to introduce the BoMI in the context of clinical therapy thus allowing a direct assessment of acceptance by therapists and clients.

研究の種類

介入

入学 (予想される)

60

段階

  • 適用できない

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Illinois
      • Chicago、Illinois、アメリカ、60611
        • 募集
        • Shirley Ryan Ability Lab
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

16年~65年 (子、大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

  1. Uninjured individuals

    Inclusion criteria:

    • Ages 18 and up.
    • Ability to follow simple commands, and to respond to questions.

    Exclusion criteria for SCI participants:

    • Does not meet the inclusion criteria.

  2. Individuals with SCI

    Inclusion criteria:

    • Age 16-65
    • Injuries at the C3-6 level, complete (ASIA A), or incomplete (ASIA B and C).
    • Able to follow simple commands
    • Able to speak or respond to questions

    Exclusion criteria:

    • Presence of tremors, spasm and other significant involuntary movements
    • Cognitive impairment
    • Deficit of visuo-spatial orientation
    • Concurrent pressure sores or urinary tract infection
    • Other uncontrolled infection, concurrent cardiovascular disease
    • Sitting tolerance less than one hour
    • Severe hearing or visual deficiency
    • Miss more than six appointments without notification
    • Unable to comply with any of the procedures in the protocol
    • Unable to provide informed consent
  3. Stroke survivors:

Inclusion criteria:

  • Recent stroke (Sub acute to early chronic, between 3 and 12 months from CVA)
  • Age less than 75 (To avoid age-related confounds)
  • Inability to operate a manual wheelchair
  • Available medical records and radiographic information about lesion locations
  • Significant level of hemiparesis (UE Fugl Meyer score between 10 and 30)
  • Presence of pathological muscle synergies in the UE (flexor and/or extensor synergy)

Exclusion criteria:

  • Aphasia, apraxia, cognitive impairment or affective dysfunction that would influence the ability to perform the experiment
  • Inability to provide informed consent
  • Severe spasticity, contracture, shoulder subluxation, or UE pain
  • Severe current medical problems, including rheumatoid arthritis or other orthopaedic impairments restricting finger or wrist movement

Additional exclusion criteria for participants enrolled in TMS procedures

  • Any metal in head with the exception of dental work or any ferromagnetic metal elsewhere in the body. This applies to all metallic hardware such as cochlear implants, or an Internal Pulse Generator or medication pumps, implanted brain electrodes, and peacemaker.
  • Personal history of epilepsy (untreated with one or a few past episodes), or treated patients
  • Vascular, traumatic, tumoral, infectious, or metabolic lesion of the brain, even without history of seizure, and without anticonvulsant medication
  • Administration of drugs that potentially lower seizure threshold [REF], without concomitant administration of anticonvulsant drugs which potentially protect against seizures occurrence
  • Change in dosage for neuro-active medications (Baclophen, Lyrica, Celebrex, Cymbalta, Gabapentin, Naprosyn, Diclofenac, Diazepam, Tramadol, etc) within 2 weeks of any study visit.
  • Skull fractures, skull deficits or concussion within the last 6 months
  • unexplained recurring headaches
  • Sleep deprivation, alcoholism
  • Claustrophobia precluding MRI
  • Pregnancy

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:他の
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:独身

武器と介入

参加者グループ / アーム
介入・治療
実験的:SCI

We will consider two methods for integrating motions and EMG signals:

  1. Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.
  2. Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty.
実験的:STROKE

We will consider two methods for integrating motions and EMG signals:

  1. Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.
  2. Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty.
実験的:UNIMPAIRED

We will consider two methods for integrating motions and EMG signals:

  1. Direct methods. Signals extracted from the latent EMG space will directly contribute to the control of the external device. We will integrate EMG and IMU in two ways. In a first scenario, EMG and IMU will be given variable weight in the control. In a second scenario (perturbative method) the distance of ongoing muscle patterns from a desired set of strategies will modulate the mapping from body to cursor motions in the form of assistive (i.e. the cursor moves faster towards the target) or resistive (i.e. the cursor slows down) influences on cursor movement.
  2. Indirect Methods. Signals extracted by EMG will modulate the feedback offered to the learner to penalize deviations from desired muscle patterns. When multiple ways to perform a movement are offered by redundancy, (i.e., by the multiplicity of muscles compared to task demands), the brain chooses solutions that minimize noise and uncertainty.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Time
時間枠:during the intervention
Changing time to task completion
during the intervention

二次結果の測定

結果測定
メジャーの説明
時間枠
Muscle activity
時間枠:baseline, during the procedure, at 1 week follow-up
EMG activity in targeted muscles
baseline, during the procedure, at 1 week follow-up
Cortico spinal connectivity
時間枠:baseline, immediately after the intervention, at 1 week follow-up
Motor evoked potentials in selected muscles following TMS stimulation of M1
baseline, immediately after the intervention, at 1 week follow-up

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

スポンサー

捜査官

  • 主任研究者:Ferdinando Mussa-Ivaldi, PhD、Northwestern University

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2020年1月20日

一次修了 (予想される)

2024年8月1日

研究の完了 (予想される)

2024年8月1日

試験登録日

最初に提出

2020年8月21日

QC基準を満たした最初の提出物

2020年11月17日

最初の投稿 (実際)

2020年11月24日

学習記録の更新

投稿された最後の更新 (実際)

2020年11月24日

QC基準を満たした最後の更新が送信されました

2020年11月17日

最終確認日

2020年11月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する